List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 199 studies with search of: Niacin OR "Nicotinic Acid" OR Nicotinamide
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Completed
Has Results 		To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: ezetimibe/simvastatin + niacin (ER);   Drug: Comparator: Placebo to ezetimibe/simvastatin;   Drug: Comparator: niacin (ER) tablet;   Drug: Comparator: ezetimibe (+) simvastatin;   Drug: Comparator: Placebo to Niacin (ER);   Drug: Comparator: ezetimibe/simvastatin and niacin (ER);   Drug: Comparator: ezetimibe and simvastatin;   Drug: Comparator: Placebo to niacin (ER)
2 Unknown † Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Condition: Elevated Lipoprotein(a) Levels
Interventions: Drug: Nicotinic acid (niacin);   Drug: Placebo
3 Completed
Has Results 		A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: niacin + laropiprant;   Drug: Comparator: niacin;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
4 Recruiting Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
Conditions: Chronic Renal Failure;   Haemodialysis
Interventions: Drug: nicotinamide;   Drug: sevelamer;   Drug: cinacalcet
5 Completed
Has Results 		A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Comparator: ER niacin (+) laropiprant;   Drug: Comparator: ER niacin;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
6 Active, not recruiting A Study to Evaluate Efficacy and Safety of Extended-Release Niacin (+) Laropiprant (+) Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
Conditions: Primary Hypercholesterolemia;   Dyslipidemia
Interventions: Drug: ER niacin/laropiprant/simvastatin;   Drug: ER niacin/laropiprant;   Drug: Simvastatin;   Drug: Placebo to match simvastatin
7 Active, not recruiting The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
Condition: Healthy Volunteers
Intervention: Drug: Immediate Release Niacin, Extended Release Niacin, Endotoxin
8 Recruiting Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery
Condition: Ischemic Stroke
Interventions: Drug: Extended-Release Niacin;   Drug: Placebo
9 Completed Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Condition: Opioid Abuse
Interventions: Drug: Niacin;   Drug: Oxycodone HCL plus Niacin;   Drug: Placebo;   Drug: Oxycodone HCl
10 Unknown † Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)
Conditions: Coronary Disease;   Hypolipoproteinemia
Interventions: Behavioral: physical exercise;   Drug: niaspan (extended-release niacin);   Drug: niacin;   Other: control
11 Completed Role of Prostaglandins on Niacin-Induced Flushing
Condition: Flushing
Intervention: Drug: Niacin and aspirin
12 Completed SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia
Condition: Dyslipidemia
Intervention: Drug: Slo-Niacin, atorvastatin
13 Completed Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
Condition: Healthy Volunteers
Interventions: Drug: Niacin;   Other: Placebo
14 Completed Niacin/Laropiprant and Endothelial Function
Condition: Coronary Heart Disease
Interventions: Drug: Niacin/laropiprant;   Drug: Placebo
15 Completed
Has Results 		Extended Niacin/Laropiprant in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus Type 2
Interventions: Drug: ER niacin/laropiprant;   Drug: Comparator : placebo (unspecified)
16 Recruiting Niacin and Endothelial Function in Early CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Niacin;   Drug: Active Placebo
17 Completed Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Drug: extended release (ER) niacin/laropiprant/simvastatin;   Drug: ER niacin/laropiprant;   Drug: simvastatin;   Drug: Placebo to simvastatin
18 Active, not recruiting Niacin, N-3 Fatty Acids and Insulin Resistance
Conditions: Metabolic Syndrome;   Hypertriglyceridemia
Interventions: Drug: omega-3 acid ethyl esters;   Drug: extended release niacin;   Drug: placebo;   Drug: combined treatment
19 Recruiting Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Conditions: Dialysis;   Cardiovascular Disease;   Atherosclerosis;   Inflammation
Intervention: Drug: Extended Release Nicotinic Acid (Niaspan)
20 Active, not recruiting Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions
Conditions: Central Retinal Vein Occlusion;   Branch Retinal Vein Occlusion
Intervention: Drug: nicotinic acid

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services